AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is focused on building and managing a strategic reserve of The Open Network (TON) tokens and developing the Telegram ecosystem. The firm implements a treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, the Company provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform. The company is also advancing therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients. The firm engages in the drug development process and provides strategic counsel to guide development of immunotherapy assets and asset combinations.
How did ATON's recent EPS compare to expectations?
The most recent EPS for AlphaTON Capital Corp is $, expectations of $.
How did AlphaTON Capital Corp ATON's revenue perform in the last quarter?
AlphaTON Capital Corp revenue for the last quarter is $
What is the revenue estimate for AlphaTON Capital Corp?
According to of Wall street analyst, the revenue estimate of AlphaTON Capital Corp range from $ to $
What's the earning quality score for AlphaTON Capital Corp?
AlphaTON Capital Corp has a earning quality score of B/41.609203. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does AlphaTON Capital Corp report earnings?
AlphaTON Capital Corp next earnings report is expected in 2026-04-22
What are AlphaTON Capital Corp's expected earnings?
AlphaTON Capital Corp expected earnings is $, according to wall-street analysts.
Did AlphaTON Capital Corp beat earnings expectations?
AlphaTON Capital Corp recent earnings of $ expectations.